Evidence map›Paper›PMID 37924473›Full record

ReviewInflammopharmacology2023

Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches.

Masoumeh Gholami, Mehdi Sadegh, Masoumeh Koroush-Arami, Shaghayegh Norouzi, Rasoul Jafari Arismani, Erfan Asadi, Mohammad Amini, Nahid Khodayari

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Masoumeh GholamiDepartment of Physiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran. ma.gholami@arakmu.ac.ir.ORCID http://orcid.org/0000-0002-6746-0488
Mehdi SadeghDepartment of Physiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Masoumeh Koroush-AramiDepartment of Neuroscience, School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shaghayegh NorouziMarkey Cancer Center, University of Kentucky, Lexington, KY, USA.
Rasoul Jafari ArismaniDepartment of Urologic Surgery, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Erfan AsadiMedical Student, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Mohammad AminiMedical Student, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Nahid KhodayariDepartment of Physiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Arak University of Medical Sciences · IRIran University of Medical Sciences · IRUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acetylsalicylic acid (ASA), also known as aspirin, was discovered in 1897 as an acetylated form of salicylate. It has been widely used for its anti-inflammatory and antiplatelet effects. It is commonly used for its cardiovascular benefits and is prescribed as secondary prophylaxis after a heart attack. Furthermore, low-dose, long-term ASA is used to reduce the risk of heart attack and stroke in individuals without prior cardiovascular disease. Acetylsalicylic acid acts as a non-selective inhibitor of cyclooxygenase (COX), which inhibits the synthesis of prostaglandins and prevents pro-inflammatory cytokines. Findings suggest that targeting cytokines and growth factors could be a potential therapeutic strategy for reducing neuroinflammation and slowing down the progression of dementia. Additionally, prostaglandins contribute to synaptic plasticity and can act as retrograde messengers in synapses. Research has implicated COX-1, one of the isoforms of the enzyme, in neuroinflammation and neurodegenerative disorders. The inhibition of COX-1 might potentially prevent impairments in working memory and reduce neuroinflammation caused by beta-amyloid proteins in some conditions, such as Alzheimer's disease (AD). Cyclooxygenase-2, an inducible form of the enzyme, is expressed in cortical and hippocampal neurons and is associated with long-term synaptic plasticity. The inhibition or knockout of COX-2 has been shown to decrease long-term potentiation, a process involved in memory formation. Studies have also demonstrated that the administration of COX-2 inhibitors impairs cognitive function and memory acquisition and recall in animal models. There remains a debate regarding the effects of aspirin on dementia and cognitive decline. Although some studies suggest a possible protective effect of non-steroidal anti-inflammatory drugs, including aspirin, against the development of AD, others have shown inconsistent evidence. This review provides an overview of the effects of ASA or its active metabolite salicylate on learning, memory, and synaptic plasticity.

Indexed as

Alzheimer DiseaseMyocardial InfarctionAnimalsAnti-Inflammatory AgentsAspirinCyclooxygenase 2CytokinesHumansMemory DisordersNeuroinflammatory DiseasesProstaglandinsAnti-Inflammatory AgentsAspirinCyclooxygenase 2CytokinesProstaglandinsAcetylsalicylic acidAlzheimerCyclooxygenaseDementiaSynaptic plasticity

Identifiers

PMID37924473
OpenAlexW4388338299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.